CCM
PACB icon

Coldstream Capital Management’s Pacific Biosciences PACB Stock Holding History

Coldstream Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-73
Closed -$86 – 2657
2025
Q1 		$86 Buy
+73
New +$112 ﹤0.01% 3515

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coldstream Capital Management's PACB Position: Q2 2025 in Review

Coldstream Capital Management sold out of Pacific Biosciences (PACB) in Q2 2025, closing a stake of 73 shares — an estimated $86 sold.

Coldstream Capital Management first reported a position in PACB in Q1 2025 and held it in 1 quarter. The position peaked at $86 in Q1 2025. 207 funds tracked by Wall St. Rank hold PACB as of Q2 2025.

  • Coldstream Capital Management reported no remaining Pacific Biosciences position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 73 Pacific Biosciences shares in Q2 2025, an estimated $86.
  • Coldstream Capital Management first reported a position in Pacific Biosciences in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Pacific Biosciences position peaked at $86 in Q1 2025.
  • 207 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.